The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium

References

• Capanna R, Coia LR, Coleman R, et al. editors. Textbook of Bone Metastases. Hoboken, NJ: John Wiley and Sons; 2005. p 105
   Google Scholar
• Rubens RD, Coleman RE. Bone metastases. In: Abeloff MD, Armitage JO, Lichter AS, et al., editors. Clinical oncology. New York: Churchill Livingstone; 1995. p 643-65
   Google Scholar
• Crump M, Gluck S, Tu D, et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol 2008;26:37-43
   PubMed Web of Science ®Google Scholar
• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s.
   PubMed Web of Science ®Google Scholar
• Sugiura H, Sugiura T, Mitsudomi T. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 2008;466:729-36
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87
   PubMed Web of Science ®Google Scholar
• Henry D, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body J-J, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22
   PubMed Web of Science ®Google Scholar
• Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-90
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82
   PubMed Web of Science ®Google Scholar
• Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21
   PubMed Web of Science ®Google Scholar
• Hoefeler H, Duran I, Hechmati G, et al. Health resource utilization associated with skeletal-related events by tumour type in patients with bone metastases/lesions: European analysis of a prospective multinational observational study. Poster presented at European Multidisciplinary Cancer Congress (ECCO); Stockholm, September 2011
   Google Scholar
• Hechmati G, Cure S, Gouépo A, et al. Cost of skeletal-related events in patients with bone metastases to solid tumours based on the health resource utilization collected in a prospective European multinational observational study. Value in Health 2011;14:455
   Google Scholar
• Gunther O, Body J-J, Sleeboom H, et al. Cost of skeletal complications from bone metastases: results from a retrospective European study. Support Care Cancer 2012;20(Suppl 1):S372
   Google Scholar
• Gerlier L, De Vos C, Lamotte M, et al. Epidemiology of idiopathic thrombocytopenic purpura in Belgium assessed using Hospital records. ISPOR 11th Annual European Congress, Athens, 10–12 November 2008
   Google Scholar
• Spaepen E, Demarteau N, Van Belle S, et al. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals. Oncologist 2008;13:596-607
   Google Scholar
• Spaepen E, Merchant S, Neslusan C, et al. Costs and outcomes of nosocomial pneumonia in a sample of Belgian hospitals. ISPOR 9th Annual European Congress, Copenhagen, 28–31 October 2006
   Google Scholar
• Annemans L, Rémy V, Lamure E, et al. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium. J Med Econ 2008;11:135-50
   PubMedGoogle Scholar
• SPF Santé Publique. Cellule Technique de traitement de données relatives aux hôpitaux. Banque Nationale de Données Diagnostic médical/soins et coût. 2011. https://tct.fgov.be/webetct/etct-web/html/fr/index.jsp (Accessed 3 July 2012)
   Google Scholar
• Cleemput I, Van Wilder P, Vrijens F et al. Richtlijnen voor farmacoeconomische evaluaties in België. Health Technology Assessment (HTA). Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE); 2008. KCE Reports 78A (D/2008/10.273/23)
   Google Scholar
• Powell C. The Delphi technique: myths and realities. J Adv Nursing 2003;41:376-82
   PubMed Web of Science ®Google Scholar
• Barlev A, Song X, Ivanov B, et al. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010;16:693-702
   PubMed Web of Science ®Google Scholar
• UK Government National Archives. Department of Health. Payment by Results (PbR) in 2008–09. http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Managingyourorganisation/Financeandplanning/NHSFinancialReforms/DH_081238 (Accessed 3 July 2012)
   Google Scholar
• World Health Organization. CHOosing Interventions that are Cost-Effective (WHO-CHOICE). http://www.who.int/choice/country/deu/cost/en/ (Accessed 3 July 2012)
   Google Scholar